Sitemap

Pages

• Our strategy
  • Our strategy
  • Neurodegeneration
    • Motor Neuron Disease Translational Challenge
    • MND collaborative partnership
    • £30m over five years to the UK Dementia Research Institute
    • Apply for the £1m Primer Fund
  • Respiratory health
    • Chronic Respiratory Infection Translational Challenge
      • How to apply for funding
      • Apply for the repurposing fund
      • Resources
    • COVID-19
      • Coronavirus (COVID-19) therapeutics: £10 million call for rapid deployment
        • Almitrine
        • ATTACC
        • ATTRACT
        • DEFEAT-COVID study
        • FaST for COVID
        • FLARE Trial
        • IONIC Trial
        • PIONEER Trial
        • PROTECT-V
        • RUX-COVID
        • RAVEN
        • SFX-01
        • SPIKE-1 Trial
        • The COVASE study
• Homepage New
• About us
  • Who we are
  • Our strategy
  • How we are funded
  • Our people
  • Our impact
  • Reports and statements
    • Our commitment to the environment
    • Equity, diversity and inclusion at LifeArc
    • Bribery and Corruption statement
    • Safeguarding Policy
    • Modern slavery statement
    • Supplier Code of Conduct
  • Governance and structure
    • Our Management Team
    • Articles of Association
    • Strategic Advisory Council 
    • Our Trustees
• Funding
  • About LifeArc Ventures
    • Our ventures team
    • A selection of our portfolio
    • News
    • Contact
  • Rare disease research funding
    • Muscular Dystrophy Translational Research Fund
    • Philanthropic Fund
      • The LifeArc Philanthropic Fund
      • Funded projects
      • Panel members
      • Frequently asked questions
      • Contact the Philanthropic Fund
    • LifeArc & Action Medical Research Fund
    • LifeArc & GOSH Charity Fund
    • Motor Neurone Disease Translational Research Fund
    • LifeArc Gene Therapy Innovation Fund
      • Apply for the LifeArc Gene Therapy Innovation Fund
    • LifeArc-CSO Fund for Scottish Translational Researchers
  • Development Gap Fund
• Working with us
  • Our partners
  • Support for MRC researchers
  • Helping charities
  • Advise & Connect: Covid-19
    • About Advise & Connect
    • How to apply
    • FAQs
    • Apply now
    • Contact the Advise & Connect team
  • Available technologies
    • Therapeutics (LifeArc)
    • Therapeutics (MRC)
    • Diagnostics
    • Other technologies
    • Research tools and reagents
    • Success stories
  • Submit your idea
• Careers
  • Working at LifeArc
  • Our culture
  • Benefits and rewards
  • How to apply
  • Job vacancies
  • Fellowships
    • Overview of LifeArc Fellowships
    • LifeArc-AUTM technology transfer career training fellowships
      • 2020-2021 Fellows
      • 2019-2020 Fellows
      • 2018-2019 Fellows
      • 2017-2018 Fellows
    • The Technology Transfer Fellows Programme
      • Technology Transfer Alumni
      • Dr Ukrit Angkawinitwong
      • Dr Diana Alexieva
      • Dr Elliott Jennings
      • Dr Richard Kaschula
      • Dr Jennifer Pritchard
      • Dr Laura Stennett
      • Dr Joo-Hee Sir
  • Industrial placements
• News
  • Latest news
  • Case studies
  • Reports and publications
  • Sign-up to our newsletter
  • Media contacts
• Capabilities
  • Capabilities overview
  • Drug discovery
    • Drug discovery FAQs
  • Antibody humanisation
  • IP management and technology transfer
  • Diagnostics development
    • About diagnostics development
      • TB-MBLA
    • Diagnostics FAQs
• Contact us
  • Sign up for news updates
    • Sign up for updates on MND
  • Newsletter sign-up
  • Unsubscribe
• Pharma/Biotech
  • Antibody humanisation
• Research Organisation
• Medical Charity
• Cookie policy
• Cookie policy
• Privacy policy
• Academic Scientist
• Contact the LifeArc & MND Association Fund